Document is current
Any future updates will be listed below
-
Authors
Briley, P. M.
Webster, L.
Lankappa, S.
Pszczolkowski, S.
McAllister-Williams, R. H.
Liddle, P. F.
Auer, D. P.
Morriss, R.
-
Funding
Funding for this research was provided by:
NIHR Nottingham Biomedical Research Centre
Efficacy and Mechanism Evaluation Programme (16/44/02)
Efficacy and Mechanism Evaluation Programme (16/44/02)
Efficacy and Mechanism Evaluation Programme (16/44/02)
Efficacy and Mechanism Evaluation Programme (16/44/02)
Efficacy and Mechanism Evaluation Programme (16/44/02)
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 5 June 2024
First Online: 27 June 2024
Competing interests
: R.M. has received funding for research from Electromedical Products, Inc. and fees for participation in a Data Monitoring Ethics Committee for two trials in depression from Novartis plc. R.H.M.-W. declares fees for consulting and giving lectures from Janssen-Cilag, LivaNova, Lundbeck, P1Vital, Sage Therapeutics, Sothema and Takeda. No other potential conflicts of interest are reported for any of the other authors. No third parties have been involved in the study design, analysis and writing of the manuscript.
